It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

• Główni autorzy: Ken Akao (Autor), Yuko Oya (Autor), Takaya Sato (Autor), Aki Ikeda (Autor), Tomoya Horiguchi (Autor), Yasuhiro Goto (Autor), Naozumi Hashimoto (Autor), Masashi Kondo (Autor), Kazuyoshi Imaizumi (Autor)
• Format: Książka
• Wydane: Open Exploration Publishing Inc., 2024-07-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is i...